These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Duration of remission and long-term prognosis according to the extent of disease in patients with ulcerative colitis on continuous mesalamine treatment. Bresci G; Parisi G; Capria A Colorectal Dis; 2008 Oct; 10(8):814-7. PubMed ID: 18834420 [TBL] [Abstract][Full Text] [Related]
31. Infliximab for the treatment of ulcerative colitis. Eshuis EJ; Bemelman WA; Stokkers PC Expert Rev Gastroenterol Hepatol; 2009 Jun; 3(3):219-29. PubMed ID: 19485804 [TBL] [Abstract][Full Text] [Related]
32. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of olsalazine (dipentum) in the treatment of patients with ulcerative colitis--results of a field study. Singer MV; Schmausser H; Schönfeld G Hepatogastroenterology; 2006; 53(69):317-21. PubMed ID: 16795963 [TBL] [Abstract][Full Text] [Related]
34. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Simrén M; Axelsson J; Gillberg R; Abrahamsson H; Svedlund J; Björnsson ES Am J Gastroenterol; 2002 Feb; 97(2):389-96. PubMed ID: 11866278 [TBL] [Abstract][Full Text] [Related]
36. Ulcerative colitis: current medical therapy and strategies for improving medication adherence. Zhang Z; Kennedy H Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):1-8. PubMed ID: 19011573 [TBL] [Abstract][Full Text] [Related]
37. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193 [TBL] [Abstract][Full Text] [Related]
38. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Sandborn WJ Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of cyclosporin with corticotropin for refractory ulcerative colitis. Okamura S; Aoki H; Ohashi S; Urano F; Shimodaira M; Kanamori S; Ishikawa H; Segawa K Hepatogastroenterology; 2003; 50(49):91-4. PubMed ID: 12629999 [TBL] [Abstract][Full Text] [Related]
40. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. D'Haens G; Sandborn WJ; Feagan BG; Geboes K; Hanauer SB; Irvine EJ; Lémann M; Marteau P; Rutgeerts P; Schölmerich J; Sutherland LR Gastroenterology; 2007 Feb; 132(2):763-86. PubMed ID: 17258735 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]